UK specialist wound treatment business BioMonde has received £3.5 million investment in a round involving Oxford Capital and Finance Wales.

BioMonde has developed a treatment that uses maggots to heal wounds that are hard to treat. The investment will help create a production base in the US and launch into the American market.

Larval Debridement Therapy, also known as maggot treatment, is a long established method to clean chronic wounds which do not respond to other treatments.

Gareth Kempson, Chief Executive Officer, BioMonde, said: “This investment will enable BioMonde to drive the next phase of its growth and development, entry into the largest medical device market in the world.

“The US has many of the same chronic disease challenges of any health system but on a larger scale and we want to be well positioned to provide the clinical and cost effective response to issues presented by chronic wounds.”